Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Trading Up 0% - Still a Buy?

Key Points

• OACC shares were essentially unchanged at $10.7810 during Wednesday’s trading, with volume falling 86% below the average session level.
• Analyst sentiment remains negative: Weiss Ratings upgraded the stock slightly from “sell (d)” to “sell (d+),” while MarketBeat reports an average rating of “Sell” from one analyst.
• The SPAC reported quarterly earnings of $0.07 per share, while several institutional investors—including Goldman Sachs, Moore Capital, and Millennium Management—recently initiated or increased positions.

Shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Get Free Report) rose 0% during mid-day trading on Wednesday . The stock traded as high as $10.78 and last traded at $10.7810. Approximately 3,538 shares were traded during trading, a decline of 86% from the average session volume of 26,110 shares. The stock had previously closed at $10.78.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Oaktree Acquisition Corp. III Life Sciences from a "sell (d)" rating to a "sell (d+)" rating in a report on Thursday, August 13th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of "Sell".

Oaktree Acquisition Corp. III Life Sciences Price Performance

The firm's fifty day simple moving average is $10.73 and its 200-day simple moving average is $10.69.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.07 earnings per share for the quarter.

Institutional Trading of Oaktree Acquisition Corp. III Life Sciences

Several institutional investors and hedge funds have recently made changes to their positions in OACC. Goldman Sachs Group Inc. purchased a new stake in Oaktree Acquisition Corp. III Life Sciences in the 1st quarter worth approximately $5,417,000. Moore Capital Management LP acquired a new position in Oaktree Acquisition Corp. III Life Sciences in the 2nd quarter valued at $5,502,000. Millennium Management LLC purchased a new position in shares of Oaktree Acquisition Corp. III Life Sciences during the 1st quarter worth $4,848,000. Lighthouse Investment Partners LLC lifted its stake in shares of Oaktree Acquisition Corp. III Life Sciences by 88.9% during the 2nd quarter. Lighthouse Investment Partners LLC now owns 850,000 shares of the company's stock worth $8,882,000 after purchasing an additional 400,000 shares during the period. Finally, Sculptor Capital LP boosted its holdings in shares of Oaktree Acquisition Corp. III Life Sciences by 100.0% during the second quarter. Sculptor Capital LP now owns 500,000 shares of the company's stock worth $5,225,000 after purchasing an additional 250,000 shares during the last quarter.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences NASDAQ: OACC is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source